Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-63.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.50 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -62.66% |
| Return on Assets (Trailing 12 Months) | -39.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.65 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.85 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.81 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.13M |
| Free Float | 31.27M |
| Market Capitalization | $375.38M |
| Average Volume (Last 20 Days) | 0.26M |
| Beta (Past 60 Months) | 0.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.78% |
| Percentage Held By Institutions (Latest 13F Reports) | 63.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |